Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ:
VERO), a global medical aesthetic technology leader, announced
financial results for the three and six months ended June 30, 2024.
Second Quarter 2024 Summary & Recent
Progress:
- Company continues to execute
against Transformational Plan
- Cash used in operations of $1.3
million, down 37% year-over-year and down 54%
quarter-over-quarter
- Total revenue of $16.6 million,
down 17% year-over-year, but in-line with second quarter estimate
of at “least $16.5 million”.
- Gross margin up 62 basis points
year-over-year to 71.5%, combined with a 13% decrease in operating
expenses year-over-year, drives 3% reduction in GAAP operating loss
year-over-year
- Adjusted EBITDA loss of $4.1
million, up 4% year-over-year, despite 17% revenue decline
- On May 28, 2024, the Company
announced a $35 million debt-to-equity exchange transaction,
significantly reducing the Company’s debt balance and bringing the
Company back into compliance with the Nasdaq Minimum Equity
Requirement.
- On June 3, 2024, the Company
announced that it received a medical device license issued by
Health Canada to market the Venus Versa Pro system in Canada.
- On June 17, 2024, the Company
announced that that it has entered a new strategic skin resurfacing
and skin tightening device supply arrangement with Skin Laundry
Holdings, Inc.
- On June 27, 2024, the Company
announced the successful completion of its NEXThetics events held
across several major cities in North America. NEXThetics events
bring together Venus Concept’s network of aesthetic leaders and
practitioners and have seen a significant increase in popularity
and attendance.
Management Commentary:
“Second quarter revenue results met the
expectations we outlined on our first quarter report,” said Rajiv
De Silva, Chief Executive Officer of Venus Concept. “Aesthetic
capital equipment sales continue to be challenged by macroeconomic
headwinds and as expected, our revenue results outside the U.S.
continue to be impacted by the strategic initiatives to exit
certain unprofitable direct market. However, we importantly
continue to see evidence that our efforts to reposition the
business over the last eighteen months have been proving
successful. We are enhancing our cash flow profile – as evidenced
by the 47% reduction year-over-year in cash used in operations over
the first six months of 2024 - and remain focused on enhancing our
balance sheet condition and enhancing the Company’s foundation to
support long-term, sustainable, profitability and growth in the
future.”
Second Quarter 2024 Financial Results:
|
|
Three Months Ended June 30, |
|
|
|
|
|
2024 |
|
|
2023 |
|
|
|
|
|
(dollars in thousands) |
|
|
|
Revenues by region: |
|
|
|
|
|
|
|
|
|
|
United States |
|
$ |
9,280 |
|
|
$ |
9,757 |
|
|
|
International |
|
|
7,302 |
|
|
|
10,318 |
|
|
|
Total revenue |
|
$ |
16,582 |
|
|
$ |
20,075 |
|
|
|
|
|
Three Months Ended June 30, |
|
|
|
|
|
|
|
|
|
|
|
2024 |
|
|
2023 |
|
|
Change |
|
(in thousands, except
percentages) |
|
$ |
|
|
% of Total |
|
|
$ |
|
|
% of Total |
|
|
$ |
|
|
% |
|
Revenues by product: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Venus Prime /
Subscription—Systems |
|
$ |
4,517 |
|
|
27.2 |
|
|
$ |
4,311 |
|
|
|
21.5 |
|
|
$ |
206 |
|
|
|
4.8 |
|
Products—Systems |
|
|
8,588 |
|
|
51.8 |
|
|
|
12,313 |
|
|
|
61.3 |
|
|
|
(3,725 |
) |
|
|
(30.3 |
) |
Products—Other |
|
|
2,647 |
|
|
16.0 |
|
|
|
2,586 |
|
|
|
12.9 |
|
|
|
61 |
|
|
|
2.4 |
|
Services |
|
|
830 |
|
|
5.0 |
|
|
|
865 |
|
|
|
4.3 |
|
|
|
(35 |
) |
|
|
(4.0 |
) |
Total |
|
$ |
16,582 |
|
|
100.0 |
|
|
$ |
20,075 |
|
|
|
100.0 |
|
|
$ |
(3,493 |
) |
|
|
(17.4 |
) |
Total revenue for the second quarter of 2024
decreased $3.5 million, or 17%, to $16.6 million, compared to the
second quarter of 2023. The decrease in total revenue, by region,
was driven by a 29% decrease year-over-year in international
revenue and a 5% decrease year-over-year in United States revenue.
The decrease in total revenue, by product category, was driven by a
30% decrease in products – systems revenue and a 4% decrease in
services revenue, offset partially by a 5% increase in lease
revenue and a 2% increase in products - other revenue. The
percentage of total systems revenue derived from the Company’s
internal lease programs (Venus Prime and our legacy subscription
model) was approximately 34% in the second quarter of 2024,
compared to 26% in the prior year period.
Gross profit for the second quarter of 2024
decreased $2.4 million, or 17%, to $11.8 million compared to the
second quarter of 2023. The change in gross profit was primarily
due to a decrease in revenue in our international markets driven by
the accelerated exit from unprofitable direct markets and the
effects of tighter third-party lending practices which negatively
impacted capital equipment sales in both the U.S. and international
markets. Gross margin was 71.5% of revenue, compared to 70.8% of
revenue for the second quarter of 2023.
Operating expenses for the second quarter of
2024 decreased $2.5 million, or 13%, to $17.4 million, compared to
the second quarter of 2023. The change in total operating expenses
was driven by a decrease of $1.3 million, or 16%, in selling and
marketing expenses, a decrease of $1.0 million, or 10%, in general
and administrative expenses and a decrease of $0.2 million, or 12%,
in research and development expenses. Second quarter of 2024
general and administrative expenses included approximately $0.2
million of costs related to restructuring activities designed to
improve the Company's operations and cost structure.
Operating loss for the second quarter of 2024
was $5.6 million, compared to operating loss of $5.8 million for
the second quarter of 2023.
Net loss attributable to stockholders for the
second quarter of 2024 was $20.0 million, or $3.05 per share,
compared to net loss of $7.4 million, or $1.35 per share for the
second quarter of 2023. Second quarter net loss attributable to
stockholders includes a pre-tax loss on debt extinguishment of
$10.9 million related to the debt-to-equity exchange transaction.
Adjusted EBITDA loss for the second quarter of 2024 was $4.1
million, compared to adjusted EBITDA loss of $4.0 million for the
second quarter of 2023.
As of June 30, 2024, the Company had cash and
cash equivalents of $5.7 million and total debt obligations of
approximately $46.0 million, compared to $5.4 million and $74.9
million, respectively, as of December 31, 2023.
Fiscal Year 2024 Financial Outlook:
Given the Company’s active dialogue with
existing lenders and investors and the ongoing evaluation of
strategic alternatives with various interested parties to maximize
shareholder value, the Company is not providing full year 2024
financial guidance at this time. The Company expects total revenue
for the three months ending September 30, 2024 of at least $17.0
million, representing a 3% decline year-over-year and a 3% increase
quarter-over-quarter.
Conference Call Details:
Management will host a conference call at 8:00
a.m. Eastern Time on August 13, 2024 to discuss the results of the
quarter with a question-and-answer session. Those who would like to
participate may dial 877-407-2991 (201-389-0925 for international
callers) and provide access code 13747737. A live webcast of the
call will also be provided on the investor relations section of the
Company's website at ir.venusconcept.com.
For those unable to participate, a replay of the
call will be available for two weeks at: 877-660-6853 (201-612-7415
for international callers); access code 13747737. The webcast will
be archived at ir.venusconcept.com.
About Venus Concept
Venus Concept is an innovative global medical
aesthetic technology leader with a broad product portfolio of
minimally invasive and non-invasive medical aesthetic and hair
restoration technologies and reach in over 60 countries and 10
direct markets. Venus Concept's product portfolio consists of
aesthetic device platforms, including Venus Versa, Venus Versa Pro,
Venus Legacy, Venus Velocity, Venus Viva, Venus Glow, Venus Bliss,
Venus Bliss MAX, Venus Epileve, Venus Viva MD and AI.ME. Venus
Concept's hair restoration systems include NeoGraft® and the ARTAS
iX® Robotic Hair Restoration system. Venus Concept has been backed
by leading healthcare industry growth equity investors, including
EW Healthcare Partners (formerly Essex Woodlands), HealthQuest
Capital, Longitude Capital Management, Aperture Venture Partners,
and Masters Special Situations.
Cautionary Statement Regarding
Forward-Looking Statements
This communication contains “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933, as
amended and Section 21E of the Securities Exchange Act of 1934, as
amended. Any statements contained herein that are not of historical
facts may be deemed to be forward-looking statements. In some
cases, you can identify these statements by words such as such as
“anticipates,” “believes,” “plans,” “expects,” “projects,”
“future,” “intends,” “may,” “should,” “could,” “estimates,”
“predicts,” “potential,” “continue,” “guidance,” and other similar
expressions that are predictions of or indicate future events and
future trends. These forward-looking statements include, but are
not limited to, but are not limited to, statements about our
financial performance and metrics; the growth in demand for our
systems and other products; the efficacy of the restructuring plan;
the identification and efficacy of strategic alternatives to
maximize shareholder value; the reduction in our cash burn; and the
continued implementation of turnaround plans, including debt
restructurings and financings. These forward-looking statements are
based on current expectations, estimates, forecasts, and
projections about our business and the industry in which the
Company operates and management's beliefs and assumptions and are
not guarantees of future performance or developments and involve
known and unknown risks, uncertainties, and other factors that are
in some cases beyond our control. As a result, any or all of our
forward-looking statements in this communication may turn out to be
inaccurate. Factors that could materially affect our business
operations and financial performance and condition include, but are
not limited to, those risks and uncertainties described under Part
II Item 1A—“Risk Factors” in our Quarterly Reports on Form 10-Q and
Part I Item 1A—“Risk Factors” in our Annual Report on Form 10-K for
the fiscal year ended December 31, 2023. You are urged to consider
these factors carefully in evaluating the forward-looking
statements and are cautioned not to place undue reliance on the
forward-looking statements. The forward-looking statements are
based on information available to us as of the date of this
communication. Unless required by law, the Company does not intend
to publicly update or revise any forward-looking statements to
reflect new information or future events or otherwise.
|
|
Venus Concept Inc.Condensed Consolidated
Balance Sheets(In thousands of U.S. dollars,
except share and per share data) |
|
|
|
|
|
June 30, |
|
|
December 31, |
|
|
|
2024 |
|
|
2023 |
|
ASSETS |
|
|
|
|
|
|
|
|
CURRENT ASSETS: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
5,732 |
|
|
$ |
5,396 |
|
Accounts receivable, net of allowance of $4,161 and $7,415 as of
June 30, 2024, and December 31, 2023, respectively |
|
|
24,584 |
|
|
|
29,151 |
|
Inventories |
|
|
19,782 |
|
|
|
23,072 |
|
Prepaid expenses |
|
|
1,009 |
|
|
|
1,298 |
|
Advances to suppliers |
|
|
4,540 |
|
|
|
5,604 |
|
Other current assets |
|
|
1,256 |
|
|
|
1,925 |
|
Total current assets |
|
|
56,903 |
|
|
|
66,446 |
|
LONG-TERM ASSETS: |
|
|
|
|
|
|
|
|
Long-term receivables, net |
|
|
9,479 |
|
|
|
11,318 |
|
Deferred tax assets |
|
|
1,195 |
|
|
|
1,032 |
|
Severance pay funds |
|
|
421 |
|
|
|
573 |
|
Property and equipment, net |
|
|
1,126 |
|
|
|
1,322 |
|
Operating right-of-use assets, net |
|
|
3,907 |
|
|
|
4,517 |
|
Intangible assets |
|
|
6,719 |
|
|
|
8,446 |
|
Total long-term assets |
|
|
22,847 |
|
|
|
27,208 |
|
TOTAL ASSETS |
|
$ |
79,750 |
|
|
$ |
93,654 |
|
LIABILITIES AND
STOCKHOLDERS’ EQUITY (DEFICIT) |
|
|
|
|
|
|
|
|
CURRENT LIABILITIES: |
|
|
|
|
|
|
|
|
Trade payables |
|
$ |
7,189 |
|
|
|
9,038 |
|
Accrued expenses and other current liabilities |
|
|
12,474 |
|
|
|
12,437 |
|
Note payable |
|
|
2,289 |
|
|
|
— |
|
Current portion of long-term debt |
|
|
1,297 |
|
|
|
4,155 |
|
Income taxes payable |
|
|
626 |
|
|
|
366 |
|
Unearned interest income |
|
|
1,198 |
|
|
|
1,468 |
|
Warranty accrual |
|
|
1,139 |
|
|
|
1,029 |
|
Deferred revenues |
|
|
894 |
|
|
|
1,076 |
|
Operating lease liabilities |
|
|
1,432 |
|
|
|
1,590 |
|
Total current liabilities |
|
|
28,538 |
|
|
|
31,159 |
|
LONG-TERM LIABILITIES: |
|
|
|
|
|
|
|
|
Long-term debt |
|
|
42,402 |
|
|
|
70,790 |
|
Accrued severance pay |
|
|
458 |
|
|
|
634 |
|
Deferred tax liabilities |
|
|
2 |
|
|
|
15 |
|
Unearned interest revenue |
|
|
438 |
|
|
|
671 |
|
Warranty accrual |
|
|
271 |
|
|
|
334 |
|
Operating lease liabilities |
|
|
2,613 |
|
|
|
3,162 |
|
Other long-term liabilities |
|
|
664 |
|
|
|
338 |
|
Total long-term liabilities |
|
|
46,848 |
|
|
|
75,944 |
|
TOTAL LIABILITIES |
|
|
75,386 |
|
|
|
107,103 |
|
Commitments and Contingencies
(Note 9) |
|
|
|
|
|
|
|
|
STOCKHOLDERS’ EQUITY (DEFICIT)
(Note 15): |
|
|
|
|
|
|
|
|
Common Stock, $0.0001 par
value: 300,000,000 shares authorized as of June 30, 2024 and
December 31, 2023; 7,255,277 and 5,529,149 issued and outstanding
as of June 30, 2024, and December 31, 2023, respectively |
|
|
30 |
|
|
|
30 |
|
Additional paid-in
capital |
|
|
295,320 |
|
|
|
247,854 |
|
Accumulated deficit |
|
|
(291,648 |
) |
|
|
(261,903 |
) |
TOTAL STOCKHOLDERS’ EQUITY
(DEFICIT) |
|
|
3,702 |
|
|
|
(14,019 |
) |
Non-controlling interests |
|
|
662 |
|
|
|
570 |
|
|
|
|
4,364 |
|
|
|
(13,449 |
) |
TOTAL LIABILITIES AND
STOCKHOLDERS’ EQUITY (DEFICIT) |
|
$ |
79,750 |
|
|
$ |
93,654 |
|
|
|
Venus Concept Inc.Condensed Consolidated
Statements of Operations(In thousands of U.S.
dollars, except per share data) |
|
|
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
|
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
|
Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Leases |
|
$ |
4,455 |
|
|
$ |
4,311 |
|
|
$ |
8,048 |
|
|
$ |
10,072 |
|
Products and services |
|
|
12,127 |
|
|
|
15,764 |
|
|
|
26,013 |
|
|
|
30,534 |
|
|
|
|
16,582 |
|
|
|
20,075 |
|
|
|
34,061 |
|
|
|
40,606 |
|
Cost of goods sold: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Leases |
|
|
410 |
|
|
|
721 |
|
|
|
1,887 |
|
|
|
2,450 |
|
Products and services |
|
|
4,323 |
|
|
|
5,134 |
|
|
|
8,678 |
|
|
|
10,237 |
|
|
|
|
4,733 |
|
|
|
5,855 |
|
|
|
10,565 |
|
|
|
12,687 |
|
Gross profit |
|
|
11,849 |
|
|
|
14,220 |
|
|
|
23,496 |
|
|
|
27,919 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling and marketing |
|
|
7,048 |
|
|
|
8,380 |
|
|
|
14,422 |
|
|
|
16,412 |
|
General and
administrative |
|
|
8,660 |
|
|
|
9,633 |
|
|
|
18,908 |
|
|
|
20,818 |
|
Research and development |
|
|
1,737 |
|
|
|
1,965 |
|
|
|
3,522 |
|
|
|
4,602 |
|
Total operating expenses |
|
|
17,445 |
|
|
|
19,978 |
|
|
|
36,852 |
|
|
|
41,832 |
|
Loss from operations |
|
|
(5,596 |
) |
|
|
(5,758 |
) |
|
|
(13,356 |
) |
|
|
(13,913 |
) |
Other expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign exchange (gain)
loss |
|
|
774 |
|
|
|
(178 |
) |
|
|
1,098 |
|
|
|
(530 |
) |
Finance expenses |
|
|
2,452 |
|
|
|
1,553 |
|
|
|
4,120 |
|
|
|
3,061 |
|
(Gain) loss on disposal of
subsidiaries |
|
|
— |
|
|
|
(1 |
) |
|
|
— |
|
|
|
76 |
|
Loss on debt
extinguishment |
|
|
10,901 |
|
|
|
— |
|
|
|
10,901 |
|
|
|
— |
|
Loss before income taxes |
|
|
(19,723 |
) |
|
|
(7,132 |
) |
|
|
(29,475 |
) |
|
|
(16,520 |
) |
Income tax expense |
|
|
141 |
|
|
|
189 |
|
|
|
178 |
|
|
|
424 |
|
Net loss |
|
$ |
(19,864 |
) |
|
$ |
(7,321 |
) |
|
$ |
(29,653 |
) |
|
$ |
(16,944 |
) |
Net loss attributable to
stockholders of the Company |
|
$ |
(19,951 |
) |
|
$ |
(7,409 |
) |
|
$ |
(29,745 |
) |
|
$ |
(17,066 |
) |
Net income attributable to
non-controlling interest |
|
$ |
87 |
|
|
$ |
88 |
|
|
$ |
92 |
|
|
$ |
122 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
$ |
(3.05 |
) |
|
$ |
(1.35 |
) |
|
$ |
(4.81 |
) |
|
$ |
(3.19 |
) |
Diluted |
|
$ |
(3.05 |
) |
|
$ |
(1.35 |
) |
|
$ |
(4.81 |
) |
|
$ |
(3.19 |
) |
Weighted-average number of
shares used in per share calculation: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
|
6,550 |
|
|
|
5,471 |
|
|
|
6,189 |
|
|
|
5,355 |
|
Diluted |
|
|
6,550 |
|
|
|
5,471 |
|
|
|
6,189 |
|
|
|
5,355 |
|
|
|
Venus Concept Inc.Condensed Consolidated
Statements of Cash Flows(in
thousands) |
|
|
|
|
|
Six Months Ended June 30, |
|
|
|
2024 |
|
|
2023 |
|
CASH FLOWS FROM OPERATING ACTIVITIES: |
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(29,653 |
) |
|
$ |
(16,944 |
) |
Adjustments to reconcile net
loss to net cash used in operating activities: |
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
1,952 |
|
|
|
2,032 |
|
Stock-based compensation |
|
|
578 |
|
|
|
850 |
|
Provision for expected credit losses |
|
|
444 |
|
|
|
977 |
|
Provision for inventory obsolescence |
|
|
723 |
|
|
|
674 |
|
Finance expenses and accretion |
|
|
2,526 |
|
|
|
680 |
|
Deferred tax expense (recovery) |
|
|
(176 |
) |
|
|
78 |
|
Loss on sale of subsidiary |
|
|
— |
|
|
|
76 |
|
Loss on extinguishment of debt |
|
|
10,901 |
|
|
|
— |
|
Loss on disposal of property and equipment |
|
|
19 |
|
|
|
— |
|
Changes in operating assets
and liabilities: |
|
|
|
|
|
|
|
|
Accounts receivable short-term and long-term |
|
|
5,962 |
|
|
|
6,153 |
|
Inventories |
|
|
2,567 |
|
|
|
297 |
|
Prepaid expenses |
|
|
289 |
|
|
|
207 |
|
Advances to suppliers |
|
|
1,064 |
|
|
|
132 |
|
Other current assets |
|
|
669 |
|
|
|
1,642 |
|
Operating right-of-use assets, net |
|
|
610 |
|
|
|
879 |
|
Other long-term assets |
|
|
(2 |
) |
|
|
(268 |
) |
Trade payables |
|
|
(1,611 |
) |
|
|
259 |
|
Accrued expenses and other current liabilities |
|
|
225 |
|
|
|
(4,185 |
) |
Current operating lease liabilities |
|
|
(158 |
) |
|
|
(236 |
) |
Severance pay funds |
|
|
152 |
|
|
|
154 |
|
Unearned interest income |
|
|
(503 |
) |
|
|
(887 |
) |
Long-term operating lease liabilities |
|
|
(549 |
) |
|
|
(555 |
) |
Other long-term liabilities |
|
|
(239 |
) |
|
|
(25 |
) |
Net cash used in operating activities |
|
|
(4,210 |
) |
|
|
(8,010 |
) |
CASH FLOWS FROM
INVESTING ACTIVITIES: |
|
|
|
|
|
|
|
|
Purchases of property and equipment |
|
|
(47 |
) |
|
|
(92 |
) |
Net cash used in investing activities |
|
|
(47 |
) |
|
|
(92 |
) |
CASH FLOWS FROM
FINANCING ACTIVITIES: |
|
|
|
|
|
|
|
|
Proceeds from issuance of common stock |
|
|
10 |
|
|
|
1,109 |
|
2023 Multi-Tranche Private Placement, net of costs of $367 |
|
|
— |
|
|
|
1,633 |
|
2024 Registered Direct Offering shares and warrants, net of costs
of $222 |
|
|
976 |
|
|
|
— |
|
Dividends from subsidiaries paid to non-controlling interest |
|
|
— |
|
|
|
(87 |
) |
Proceeds from Short-Term Bridge Financing By Madryn, net of costs
$238 |
|
|
2,000 |
|
|
|
— |
|
2024 Convertible Notes issued to EW, net of costs of $393 |
|
|
1,607 |
|
|
|
— |
|
Net cash provided by financing activities |
|
|
4,593 |
|
|
|
2,655 |
|
NET INCREASE (DECREASE) IN
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH |
|
|
336 |
|
|
|
(5,447 |
) |
CASH AND CASH EQUIVALENTS AND
RESTRICTED CASH — Beginning of period |
|
|
5,396 |
|
|
|
11,569 |
|
CASH AND CASH EQUIVALENTS AND
RESTRICTED CASH — End of period |
|
$ |
5,732 |
|
|
$ |
6,122 |
|
SUPPLEMENTAL
DISCLOSURES OF CASH FLOW INFORMATION: |
|
|
|
|
|
|
|
|
Cash paid for income taxes |
|
$ |
69 |
|
|
$ |
18 |
|
Cash paid for interest |
|
$ |
1,594 |
|
|
$ |
2,381 |
|
Use of Non-GAAP Financial Measures
Adjusted EBITDA is a non-GAAP measure defined as
net income (loss) before foreign exchange (gain) loss, financial
expenses, income tax expense (benefit), depreciation and
amortization, stock-based compensation and non-recurring items for
a given period. Adjusted EBITDA is not a measure of our financial
performance under U.S. GAAP and should not be considered an
alternative to net income or any other performance measures derived
in accordance with U.S. GAAP. Accordingly, you should consider
Adjusted EBITDA along with other financial performance measures,
including net income, and our financial results presented in
accordance with U.S. GAAP. Other companies, including companies in
our industry, may calculate Adjusted EBITDA differently or not at
all, which reduces its usefulness as a comparative measure. We
understand that although Adjusted EBITDA is frequently used by
securities analysts, lenders and others in their evaluation of
companies, Adjusted EBITDA has limitations as an analytical tool,
and you should not consider it in isolation, or as a substitute for
analysis of our results as reported under U.S. GAAP. Some of these
limitations are: Adjusted EBITDA does not reflect our cash
expenditures or future requirements for capital expenditures or
contractual commitments; Adjusted EBITDA does not reflect changes
in, or cash requirements for, our working capital needs; and
although depreciation and amortization are non-cash charges, the
assets being depreciated will often have to be replaced in the
future, and Adjusted EBITDA does not reflect any cash requirements
for such replacements.
We believe that Adjusted EBITDA is a useful
measure for analyzing the performance of our core business because
it facilitates operating performance comparisons from period to
period and company to company by backing out potential differences
caused by changes in foreign exchange rates that impact financial
assets and liabilities denominated in currencies other than the
U.S. dollar, tax positions (such as the impact on periods or
companies of changes in effective tax rates), the age and book
depreciation of fixed assets (affecting relative depreciation
expense), amortization of intangible assets, stock-based
compensation expense (because it is a non-cash expense) and
non-recurring items as explained below.
The following is a reconciliation of net loss to Adjusted EBITDA
for the periods presented:
Venus Concept Inc.Reconciliation of Net
loss to Non-GAAP Adjusted EBITDA |
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
|
Reconciliation of net
loss to adjusted EBITDA |
|
(in thousands) |
|
|
(in thousands) |
Net loss |
|
$ |
(19,864 |
) |
|
$ |
(7,321 |
) |
|
$ |
(29,653 |
) |
|
$ |
(16,944 |
) |
Foreign exchange (gain)
loss |
|
|
774 |
|
|
|
(178 |
) |
|
|
1,098 |
|
|
|
(530 |
) |
(Gain) loss on disposal of
subsidiaries |
|
|
— |
|
|
|
(1 |
) |
|
|
— |
|
|
|
76 |
|
Loss on debt
extinguishment |
|
|
10,901 |
|
|
|
— |
|
|
|
10,901 |
|
|
|
— |
|
Finance expenses |
|
|
2,452 |
|
|
|
1,553 |
|
|
|
4,120 |
|
|
|
3,061 |
|
Income tax expense |
|
|
141 |
|
|
|
189 |
|
|
|
178 |
|
|
|
424 |
|
Depreciation and
amortization |
|
|
977 |
|
|
|
1,010 |
|
|
|
1,952 |
|
|
|
2,032 |
|
Stock-based compensation
expense |
|
|
239 |
|
|
|
369 |
|
|
|
578 |
|
|
|
850 |
|
CEWS (1) |
|
|
— |
|
|
|
— |
|
|
|
418 |
|
|
|
— |
|
Other adjustments (2) |
|
|
238 |
|
|
|
412 |
|
|
|
1,148 |
|
|
|
1,330 |
|
Adjusted
EBITDA |
|
$ |
(4,142 |
) |
|
$ |
(3,967 |
) |
|
$ |
(9,260 |
) |
|
$ |
(9,701 |
) |
(1) In April 2022, the Canada Revenue Agency (“CRA”) initiated
an audit of the Canada Emergency Wage Subsidy Claim (“CEWS”) that
the Company filed between 2020-2021. The CRA has currently assessed
a denial of CEWS claims made by the Company in 2020 and requesting
repayment of $418. The Company disputes the CRA assessment and
intends to challenge this matter through the Tax Court or Judicial
Review.
(2) For the three and six months ended June 30, 2024 and June
30, 2023 the other adjustments are represented by restructuring
activities designed to improve the Company's operations and cost
structure.
Investor Relations Contact:
ICR Westwicke on behalf of Venus Concept:
Mike Piccinino, CFA
VenusConceptIR@westwicke.com
Venus Concept (NASDAQ:VERO)
Historical Stock Chart
From Oct 2024 to Nov 2024
Venus Concept (NASDAQ:VERO)
Historical Stock Chart
From Nov 2023 to Nov 2024